WallStreet Research(TM) Announces Availability of Updated Corporate Profile Coverage on Pressure BioSciences, Inc. (OTCQB: PBIO).
NEW YORK, NY / ACCESSWIRE / August 18, 2016 / WallStreet Research™, a top-ranked independent research firm with a history spanning over three decades, today announced that the firm has updated corporate profile coverage on Pressure BioSciences, Inc. (OTCQB:PBIO). WallStreet Research™ is ranked number one on the Google, Yahoo, and Bing search engines in both small and microcap research. An updated analyst Corporate Profile Report, together with additional information about WallStreet Research™, is available at the www.WallStreetResearch.org website.
The Corporate Profile highlights the recent accomplishments and growth plans under the guidance of the company’s management that includes CEO Mr. Richard T. Schumacher, the founder of the company. Pressure BioSciences, Inc. recently signed an exclusive, two-year co-marketing agreement with a large strategic partner named SCIEX, which offers tremendous potential for revenue growth. SCIEX is a global leader in life sciences analytical technologies and a wholly owned subsidiary of the Danaher Corporation (NYSE: DHR). The Company recently released its “next generation” PCT instrument system, and immediately announced the sale of three systems to the Children’s Medical Research Institute (CMRI) in Sydney, AU. CMRI was highlighted in a White House press release on July 16, 2016 as an official collaborator to the U.S. National Cancer Institute as part of President Obama’s Cancer Moonshot. This important and exciting program is led by Vice President Joe Biden, and has a stated goal to make huge strides to prevent cancer and enhance its early detection. Cancer Moonshot is $1 Billion dollar initiative, that has started with $195 million in new cancer funding at the National Institutes of Health (NIH) in 2016, with a reported $700 million more earmarked for 2017.
Mr. Alan Stone, Managing Director of WallStreet Research™, added: “WSR is very impressed with Pressure BioSciences’ ability to increase sales as evidenced by their recent 34% product revenue growth in the first half of 2016. WSR believes in PBI’s management; the Company’s current business strategy; recent milestone accomplishments, including the release of several key enhanced products,; successful close of over $6.3M in recent PIPE financing;, retirement of all outstanding floorless convertible notes, to reduce dilution; and strong product endorsements from worldwide key opinion leaders. WSR believes that these are key indicators of possible upside potential. We strongly believe that at current levels PBIO is highly undervalued, and may soon surpass its 52-week high. WSR has followed the company for several years prior to initiating corporate profile coverage in November, 2015.”
About Pressure BioSciences, Inc.
Pressure BioSciences, Inc. (“PBI”) (OTCQB: PBIO) develops, markets, and sells proprietary laboratory instrumentation and associated consumables to the estimated $6 billion life sciences sample preparation market. The Company’s products are based on the unique properties of both constant (i.e., static) and alternating (i.e., pressure cycling technology, or PCT) hydrostatic pressure. PCT is a patented enabling technology platform that uses alternating cycles of hydrostatic pressure between ambient and ultra-high levels to safely and reproducibly control bio-molecular interactions. To date, the Company has installed over 275 PCT systems in approximately 160 sites worldwide. There are over 100 publications citing the advantages of the PCT platform over competitive methods, many from key opinion leaders. The Company’s primary application development and sales efforts are in the biomarker discovery and forensics areas. Customers also use their products in other areas, such as drug discovery & design, bio-therapeutics characterization, soil & plant biology, vaccine development, histology, and counter-bioterror applications.
About WallStreet Research™
WallStreet Research™ (“WSR”) is a prominent research boutique led by Mr. Alan Stone, Managing Director of Alan Stone & Company, LLC (ASC). The firm specializes in the microcap and small cap investment arena, looking for emerging growth companies with strong management, unique or proprietary technology, significant market potential, financial strength, and outstanding long-term earnings growth possibilities. Mr. Stone was formerly a securities analyst and assistant portfolio manager at Merrill Lynch Asset Management, an investment analyst at Prudential Financial’s Capital Markets Group, and an investment banker with Ladenburg Thalmann & Company. The firm has offices in Los Angeles, CA, Palm Beach, FL, and New York City, NY, and is well known for discovering undervalued companies and bringing them to the attention of the investment community. ASC/WSR also arranges road shows for its publicly traded clients, before the investment community in New York City, California and Florida.
Disclaimer
The information presented herein is not to be construed as an offer to sell, nor a solicitation of an offer to purchase, any securities. This corporate profile is not a research report, but a compilation of information available to the public, which has been furnished by the featured company or gathered from other sources, in each case without independent verification, and no representations are made as to the accuracy or validity thereof. The information may include certain forward-looking statements within the meaning of Section 21E of the SEC Act of 1934, which may be affected by unforeseen circumstances or certain risks. Any investment in securities contains inherent risks and should only be done after consulting an investment professional. The featured company will pay a fee of $3,500 in cash to Alan Stone & Company LLC for preparation and distribution of this profile, including other potential fees associated with various consulting and investor relations’ services.
For complete disclaimer information, the readers are hereby referred to the Disclaimer Page at the www.WallStreetResearch.org website.
Contact / Source:
WallStreet Research™
Alan Stone, 310-444- 3940
astone@alanstone.com
Barbara Blake, 415-419- 4239
bjblake1229@att.net
www.SouthFloridaInvestmentForum.com
www.SouthernCaliforniaInvestmentForum.com
SOURCE: WallStreet Research
ReleaseID: 443962
Copyright © 1999-2013 SproutNews.com
